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Abstract
Background: Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after
intradermal administration. In this randomized controlled pilot study we investigate intranasal administration of Vacc-4x
with Endocine as adjuvant.
Methods: Safety and immunogenicity were tested in patients on effective ART. They were randomized to low, medium or
high dose Vacc-4x or adjuvant alone, administered four times at weekly intervals with no booster. Vacc-4x-specific T cell
responses were measured in vitro by proliferation and in vivo by a single DTH skin test at the end of study. Nasal and rectal
mucosal secretions were analyzed for Vacc-4x-specific antibodies by ELISA. Immune regulation induced by Vacc-4x was
assessed by functional blockade of the regulatory cytokines IL-10 and TGF-b.
Results: Vacc-4x proliferative T cell responses increased only among the vaccinated (p#0.031). The low dose group showed
the greatest increase in Vacc-4x CD8+T cell responses (p = 0.037) and developed larger DTH (p = 0.005) than the adjuvant
group. Rectal (distal) Vacc-4x IgA and IgG antibodies also increased (p = 0.043) in this group. In contrast, the high dose
generated higher nasal (local) Vacc-4x IgA (p = 0.028) and serum IgG (p = 0.030) antibodies than the adjuvant. Irrespective of
dose, increased Vacc-4x CD4+T cell responses were associated with low proliferation (r =20.82, p,0.001) and high
regulation (r = 0.61, p = 0.010) at baseline.
Conclusion: Intranasal administration of Vacc-4x with Endocine was safe and induced dose-dependent vaccine-specific T
cell responses and both mucosal and systemic humoral responses. The clinical significance of dose, immune regulation and
mucosal immunity warrants further investigation.
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Human Immunodeficiency Virus (HIV) type 1 infection is a
challenge for global health [1]. Although many infected individ-
uals have access to well tolerated and effective antiretroviral
therapy (ART), alternative treatment strategies are needed,
particularly for patients with drug resistance and individuals at
high risk of complications related to persistent chronic immune
activation [2,3].
Therapeutic HIV vaccines are designed to induce more effective
HIV-specific immune responses [4]. CD4+T cells provide
immunological support to HIV-specific CD8+T cells that are
crucial for sustained viral control [5]. Effective therapeutic
vaccination may delay treatment initiation or supplement ART
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to further suppress viral replication. Strengthened HIV-specific
cellular immune responses attained by therapeutic vaccination
may also be essential as part of a future functional cure for HIV
[6–8]. HIV protein Gag-specific T cell responses are associated
with virus control and delayed disease progression [9]. Vacc-4x is
a peptide-based therapeutic HIV vaccine corresponding to
conserved regions of Gag p24 [10]. Intradermal Vacc-4x with
recombinant granulocyte-macrophage colony stimulating factor as
adjuvant has been shown to enhance HIV-specific cellular
immune responses in patients on ART [11], induce long lasting
vaccine-specific T cell memory [12] and lower viral load set-points
after interruption of ART [13]. Furthermore, no viral mutations
within the conserved HIV p24 sequences were found in vaccinated
patients [14].
The primary and secondary objectives of this randomized
controlled pilot study were to explore safety and immunogenicity
of intranasal administration of Vacc-4x at different doses.
Intranasal administration may open for a new and easier means
of HIV vaccine delivery, which may be of special interest in
resource limited settings. Less trained personnel can administer
such vaccines, as has been demonstrated with the oral polio
vaccine. In this phase I trial, HIV- infected patients on effective
ART were vaccinated by application onto the nasal mucosa with
Vacc-4x dissolved in Endocine, an adjuvant developed for mucosal
administration [15,16]. Endocine has previously been shown to be
safe and tolerable in humans and the Endocine-adjuvanted whole
virus vaccine fulfilled the EMA/CHMP HAI criteria for a seasonal
influenza vaccine [17].
Mucosal vaccination may induce both systemic and mucosal
immune responses [15,18,19]. The latter is relevant for HIV,
which is transmitted via mucosa through sexual contact, and later
resides and replicates in mucosal tissues. In contrast to other
mucosal delivery routes that mostly induce local immune
responses, intranasal immunization may generate IgA and IgG
antibody responses at distant sites such as cervicovaginal mucosa
[20,21]. Although Vacc-4x was designed to primarily induce
systemic cellular immune responses, this study explored whether
systemic as well as nasal and rectal humoral responses would be
induced following intranasal vaccine delivery.
In chronic HIV infection, HIV-specific T cell responses may be
strongly regulated [22,23], and immune regulatory mechanisms
may therefore be important to consider in therapeutic HIV
vaccination [24]. As a secondary objective, we therefore assessed
vaccine-specific immune regulation mediated by cytokines that
potently inhibit Th1 responses as recently described by Lind et al
[25]. Our data indicate that both vaccine antigen doses and pre-
existing immune regulatory mechanisms to the vaccine antigens
may influence the outcome of mucosal therapeutic HIV vaccina-
tion.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Protocol S1 and
Checklist S1.
Study design and immunization schedule
This single-blinded, randomized study (Fig. 1) included 24
HIV-infected patients over 18 years of age, infected for more than
one year, on effective ART for at least 6 months with viral load ,
50 copies/ml, CD4+T cell count .400/ml and nadir CD4.200/
ml. Exclusion criteria were AIDS-defining illnesses, malignancies,
Figure 1. The study CONSORT diagram. Patients were randomized to either Vacc-4x with Endocine as adjuvant (right) or adjuvant alone (left).
doi:10.1371/journal.pone.0112556.g001
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chronic active infections, immunosuppressive therapy, pregnancy,
breastfeeding or unacceptable general biochemical and hemato-
logical parameters. All patients were selected from the Outpatient
Clinic, Department of Infectious Diseases, Oslo University
Hospital.
The study was sequential and dose escalating. The random
allocation sequence was generated by the monitor. Patients were
screened over a three months period and included sequentially
according to the allocated dose, interspersed with patients
randomized to adjuvant only. Randomization was blinded to
patients. The primary endpoint was safety and the number of
participants was therefore limited. Regardless, it was possible to
statistically analyze secondary endpoints in subgroups. Eighteen
patients received Vacc-4x at low (LD, 80 mg Vacc-4x), medium
(MD, 400 mg Vacc-4x) or high dose (HD, 1200 mg Vacc-4x) with
Endocine as adjuvant, whereas 6 patients received Endocine only.
All patients were given 150 ml in each nostril, loaded onto the
nasal floor while in an upright position, their head bent slightly
backwards to keep the dispersion in the nasal cavity. A total of four
doses were administered at weekly intervals with final visit at week
8.
The study was approved by the Norwegian Medicines Agency
(EudraCT 2011-000568-80) and the Norwegian Regional Ethics
Committee South East (application #2011/2012). Written
informed consent was obtained from all participants.
Peptide design and adjuvant
Vacc-4x is composed of four water-soluble, slightly modified
short peptides of 24–27 amino acids, corresponding to conserved
regions of the HIV core protein Gag p24 [10].
Endocine is a delivery system specifically developed for
intranasal vaccines. It is a lipid-based (monoolein and oleic acid)
dispersion with particles less than 100 nm. Endocine was adjusted
and tested for solubility and stability alone and in combination
with Vacc-4x.
The vaccine was prepared by the Oslo University Hospital
pharmacy on the day of administration.
Monitoring and blood sampling
Adverse events were monitored and clinical examination
performed at each visit. Blood samples for safety (general
biochemistry and hematology), CD4+ and CD8+T cell counts
and HIV RNA were analyzed by conventional methods.
Peripheral blood mononuclear cells (PBMC) were obtained from
CPT tubes (Becton Dickinson Biosciences, San Jose, CA) (BD). All
blood samples were collected prior to immunizations. Serum was
processed and stored at -70uC until further analysis.
Vacc-4x delayed type hypersensitivity test (DTH)
A Vacc-4x DTH was performed at end of study (week 8) by
intradermal injection of 400 mg Vacc-4x in 100 ml sterile water as
previously described [11]. A positive test was defined as a palpable
skin infiltrate with an induration area .10 mm2 [11]. Baseline
DTH was not performed as intradermal Vacc-4x might interfere
with mucosal antigen exposure.
T cell proliferation and regulation
Fresh PBMC were pulse-labeled with carboxyfluorescein
succinimidyl ester (CSFE) (Invitrogen Molecular Probes, OR) at
3 mM for 5 minutes before stimulation with Vacc-4x 15-mer
peptide panels at 2.5 mg/ml/peptide as detailed elsewhere [11].
The positive control was 0.5 mg/ml Staphylococcal enterotoxin B
(Sigma-Aldrich, Oslo, Norway) (S-A). 250,000 PBMC were
cultured in 200 ml serum-free culture medium (Gibco AIM V,
Invitrogen/Life technologies, San Diego, CA) at 37uC and 5%
CO2 in 96-well tissue-culture plates (Nunc, Roskilde, Denmark).
100 ml medium was renewed at day 3, and cells were harvested at
day 6 and stained with anti-CD3 Pacific Blue, anti-CD8 AmCyan
and 7-aminoactinomycin (7AAD) (BD) to exclude nonviable cells.
Vaccine-specific proliferative T cell responses were defined as
percentages of live (7AAD-) CFSEdim CD8+ or CD4+ (i.e. CD8-)
CD3+T cells. The cut-off for the proliferated CFSEdim T cell
subset was set by median fluorescence intensities equal to or below
the second proliferated generation. Net responses were calculated
by subtracting background proliferation in corresponding un-
stimulated control cultures.
To quantify antigen-induced cytokine-mediated regulation
(RAC), inhibitory monoclonal antibodies (mAbs) to interleukin-10
(IL-10) and transforming growth factor-b (TGF-b) at 10 mg/ml
final concentration were added to parallel antigen and control
cultures according to the manufacturer’s instructions (R&D
Systems Europe, Abingdon, UK). Regulation was defined as
difference in antigen-specific proliferative responses between
cultures with or without inhibitory mAbs [26].
Flow cytometry data were obtained with BD FACS Canto II
with BD Diva software v6.1.
Cytokines and chemokines
Cell culture supernatants (100 ml) were harvested 18 hours after
stimulation with Vacc-4x peptides and stored at270uC. Cytokines
and chemokines were measured using Bio-Plex XMap technology
with Luminex IS 100 (BIO-RAD, CA) and Bio-Plex manager
Software v6. StatLIA software package v3 (Brendan Scientific Inc.,
Carlsbad, CA) was used to calculate sample concentrations.
Vaccine-specific IgA and IgG antibodies in mucosal
secretions and serum
Nasal and rectal mucosal secretions were collected at week 1
and 8. After the administration of approximately 0.4 ml of saline
to both cavities using a nasal spray device (Minigrip, Apodan,
Copenhagen, Denmark), nasal fluid was absorbed onto dry filter
paper collection devices (MucoSafe, Norwegian Institute of Public
Health, Oslo, Norway). The filter papers were dried overnight and
stored at room temperature (20uC) until extraction [27].
Rectal secretions were collected as described by Kozlowski et al
[28]. A sterile swab (Sugi, Kettenbach, Eschenburg, Germany) was
pre-moistened with 50 ml saline and placed onto the rectal mucosa
6 cm from the anus for 5 minutes while the patient was lying on
one side. The swab was stored at 270uC until extraction.
Nasal and rectal secretions were eluded from filter papers and
swabs, respectively, in 1 ml 0.01 M phosphate buffered saline
(PBS) with 0.05% Tween 20 using Salivette extraction and
centrifuge tubes (Sarstedt AB, Helsingborg, Sweden). Briefly, the
roll-shaped swabs provided in the Salivette tubes were removed
and discarded. Each filter paper or swab with secretions was
placed in a Salivette tube and the cork replaced. PBS was added
through the hole in the bottom of the Salivette tube after which the
tube was left standing upside down for 15 min to saturate the
filter/swab and elude the secretions. The outer centrifuge tube was
placed over the inverted Salivette tube and carefully vortexed in
this position. Thereafter, the Salivette extraction tube in the outer
centrifuge tube was turned right side up and centrifuged at
10006g for 5 minutes. The extraction tube with the filter paper/
swab was removed and discarded, and the extract collected in the
centrifuge tube was stored at 220uC until analysis.
IgA and IgG antibodies specific for Vacc-4x and Gag p24 were
analyzed by enzyme-linked immunoabsorbent assay (ELISA).
Intranasal Therapeutic HIV Vaccine
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Vacc-4x (5 mg/ml) or Gag p24 (1 mg/ml) in sodium carbonate
buffer pH 9.5 was used as coating antigen adsorbed on F8
MaxiSorp Immuno Plates (Nunc, Roskilde, Denmark). Non-
specific protein-binding sites were blocked with 5% skimmed milk
(Oxoid, Basingstoke, UK) in PBS. Two-fold serial dilutions of both
mucosal samples and a defined pool of patient secretions in
blocking buffer were applied to the plates and incubated overnight
at 4uC. The plates were washed 5 times with PBS containing
0.05% Tween-20 and incubated for 1 hour at room temperature
with peroxidase-conjugated goat antibodies to human IgA or IgG
(S-A). After washing 7 times, bound antibodies were detected with
o-phenylene diamine (S-A) in 0.05 M phosphate-citrate buffer,
pH 5.0. Optical densities were read at 490 nm in a Thermo max
microplate reader (Molecular Devices, Sunnyvale, CA). Standard
curves were generated and antibody concentrations in arbitrary
units (U) to Vacc-4x or Gag p24 in each sample were determined
based on the defined pool of patient secretions [27]. The lowest
measurable IgA and IgG antibody levels to these antigens were
used as cut-off values. Antibody levels were related to total
concentrations of IgA or IgG to adjust for the diluting influence of
differences in the amounts of nasal spray used and variations in
secretory activity [29]. The adjusted levels were expressed as the
ratio of specific IgA or IgG antibodies per weight unit of total IgA
or IgG, respectively.
Total IgA and IgG in secretions were determined by ELISA as
described [27]. After coating the plates with affinity-purified goat
antibodies directed against human IgA (a-chain specific) and IgG
(c-chain specific) (S-A), bound Ig was detected by peroxidase-
conjugated goat antibodies to human IgA and IgG (S-A),
respectively. Purified human IgA (dimer) and IgG (pooled serum)
(Nordic Immunological Laboratories, Tilburg, the Netherlands)
were used as standards.
Serum samples were analyzed by ELISA for Vacc-4x and Gag
p24 IgG antibodies based on a defined pool of patient sera.
Statistical methods
Statistical analysis and graphics were performed by Statistica v7
(StatSoft, Tulsa, OK) using non-parametrical statistics. Mann-
Whitney U test was applied for group-wise comparisons, Wilcoxon
matched pairs test for dependent variables, and Spearman rank for
correlations. Fisher exact test was used to test proportional
differences. All data are presented as medians (interquartile ranges,
IQR). p-values ,0.05 were considered significant.
Results
Safety and tolerability
A total of 23 patients (Table 1) completed the study. One
patient in the HD group was hospitalized due to aggravation of
mild pre-study myositis and taken off ART with improved
condition before the final visit. As a result of the ART interruption
the patient was excluded from the data analysis. No serious
adverse event related to study vaccine was reported. Mild and
transient (,1 hour) soreness at the application site was frequently
reported in all groups. Mild flu-like symptoms, upper respiratory
infections and viral gastroenteritis were occasionally noted but
were not related to the vaccine. Overall, the vaccine was well
tolerated with no major changes in vital signs, laboratory
parameters, HIV RNA, CD4+ or CD8+T cell counts.
Dose-dependent Vacc-4x DTH induration at end of study
At end of study, four weeks after the last vaccine or adjuvant
dose, a Vacc-4x DTH skin test was performed to assess cellular
immune responses in vivo. Fifteen (88%) of the 17 remaining
subjects in the vaccinated group had a positive DTH compared to
4 (67%) in the adjuvant group (p= 0.271). DTH indurations
tended to be larger for the Vacc-4x group (median 39 mm2)
compared to the adjuvant group (median 24 mm2; p = 0.072).
Dose-related differences were observed; the LD group presented
significantly larger infiltrates (median 50 mm2) than the adjuvant
group (p = 0.005) with a similar trend for the HD group (median
33 mm2; p = 0.075) (Fig. 2).
Vacc-4x-induced changes in vaccine-specific CD8+ and
CD4+T cell responses
At baseline, no significant differences in Vacc-4x-specific
proliferative T cell responses were observed between any of the
four groups. The individual responses over time are shown in
Fig. 3A; increased responses were seen in 12 (71%) of the 17
vaccinated patients. Proliferative T cell responses improved in
both T cell subsets (p#0.031, Wilcoxon matched pairs test) from
baseline to week 8 (Fig. 3B). Proliferative CD8+T cell responses
increased in both the LD and HD groups compared to the
adjuvant group (p = 0.037 and 0.045, respectively) (Fig. 3C).
A selection of soluble mediators was measured in cell culture
supernatants after stimulation for 18 hours to assess early T cell
activation. At baseline, proliferative T cell responses correlated
with levels of the proinflammatory chemokine MIP-1b (CD4+
r = 0.47, p = 0.024) and inversely with the Th2 cytokine IL-13
(CD8+r =20.52, p = 0.009). At end of study, supernatant levels of
the Th1 cytokine TNF-a were higher than at baseline in the
vaccinated (p= 0.027) but not in the adjuvant group (p = 0.463).
Moreover, Vacc-4x-specific proliferative T cell responses corre-
lated with the concentration of RANTES in the vaccinated (CD4+
r = 0.72, p = 0.001; CD8+r = 0.49, p= 0.048) but not in the
adjuvant group (CD4+/CD8+r = 0.14, p = 0.787) (data not
shown).
Improved Vacc-4x T cell responses predicted by low T
cell proliferation and high T cell regulation at baseline
Irrespective of dose, increased Vacc-4x responses were most
pronounced in subjects with low baseline responses. This was
indicated by an inverse correlation between baseline proliferation
and change in proliferative T cell responses induced by Vacc-4x,
particularly in the CD4+T cell subset (r = -0.82, p,0.001).
Vacc-4x proliferative responses equal to or even lower than the
background proliferation in corresponding unstimulated control
cultures might be related to immune regulation. Therefore, Vacc-
4x-induced regulation (RAC) was explored. More subjects with
negative baseline responses relative to control cultures had
detectable Vacc-4x-induced regulation than subjects with positive
baseline responses [CD4+; 83% (n= 12) vs 27% (n= 11), p = 0.012
and CD8+; 80% (n= 10) vs 15% (n= 13), p = 0.003]. Moreover,
Vacc-4x-induced regulation at baseline correlated with the change
in Vacc-4x-specific proliferation in the CD4+T cell subset
(r = 0.61, p = 0.010) (Fig. 4A), suggesting that regulation at
baseline was beneficial. In group-wise analysis this association
was significant only for the LD group (r = 0.83, p = 0.042).
We also examined factors related to change in Vacc-4x
regulation over time in response to vaccination. Increased
regulation in the CD8+T cell subset was associated with high
baseline Vacc-4x-specific proliferation (r = 0.74, p,0.001) and low
baseline regulation (r =20.71, p = 0.001). Dose-dependent regu-
lation seemed to occur as an increase in RAC was found only in the
HD (p= 0.043) and possibly MD (p= 0.075) groups, but not in the
LD or adjuvant groups (data not shown).
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Finally, when the Vacc-4x DTH in vivo responses, the
proliferative responses and regulation in vitro were compared,
the DTH responses were best associated with Vacc-4x-induced
regulation in the CD4+T cell subset (r =20.61, p = 0.010)
(Fig. 4B).
Dose-dependent Vacc-4x humoral responses in mucosal
secretions and serum
Nasal and rectal mucosal secretions were collected at baseline
and end of study from 23 (100%) and 22 (96%) of the participants,
respectively. IgA and IgG antibodies to Vacc-4x and HIV p24
protein were detected in all patient sera at baseline, but not in
HIV-seronegative control samples (data not shown).
In rectal mucosal samples at baseline, Vacc-4x IgA and IgG
antibodies were detected in 91% and 64% (i.e. above assay cut-
off), respectively, and correlated with the anti-p24 levels (IgA
r= 0.53, p = 0.012; IgG r= 0.78, p,0.001). Nasal Vacc-4x IgA
and IgG antibody levels were above cut-off in 78% and 61%,
respectively. During the study period, a significant increase in
distal (rectal) mucosal Vacc-4x IgA and IgG antibodies was seen
only among LD patients (both p= 0.043, Wilcoxon matched pairs
test). Moreover, the LD group was the only one where rectal Vacc-
4x IgA antibodies increased significantly compared to the adjuvant
group (Fig. 5, Mann-Whitney U test). In contrast, an increase in
local (nasal) IgA antibodies was seen in the two higher dose groups
compared to the adjuvant group (Fig. 5) and the baseline levels as
well as changes from baseline were larger than in rectal secretions.
In serum, Vacc-4x IgG antibody levels increased significantly only
in the HD group compared to the adjuvant group (p= 0.030)
(Fig. 5).
Finally, changes in cellular and humoral responses to Vacc-4x
after vaccination were compared. Negative correlations were
found between systemic proliferative T cell responses and nasal Ig
antibody levels (IgG r#20.48, p#0.05, CD4+ and CD8+; IgA
Table 1. Cohort characteristics.
Adjuvant (n =6) Vaccine (n =17) p
Male: Female 6:0 16:1
Caucasian: Black 6:0 16:1
Age (years) 43.7 (39.7–56.4)* 48.8 (39.5–4.4) ns
Time since diagnosis (years) 8.9 (4.0–10.9) 7.5 (5.1–12.4) ns
Time on ART (years) 3.1 (2.6–4.6) 3.5 (2.4–9.4) ns
Nadir CD4 (cells/ml) 254 (200–280) 301 (240–362) ns
CD4 (cells/ml) 677 (578–748) 775 (660–985) ns
CD8 (cells/ml) 1104 (900–1374) 909 (778–1123) ns
HIV RNA (copies/ml) ,20 ,20 ns
*Median (interquartile range).
doi:10.1371/journal.pone.0112556.t001
Figure 2. Vacc-4x DTH skin tests at week 8. Induration areas in the adjuvant and the vaccinated group (left panel) and the four dose groups
(right panel). Adj = adjuvant, LD = low, MD = median and HD = high dose. Data are given as medians, interquartile and overall ranges. Differences
between dose groups and the adjuvant group with p-values less than 0.10 are indicated (Mann-Whitney U test).
doi:10.1371/journal.pone.0112556.g002
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r =20.47, p= 0.058, CD8+) as well as serum Vacc-4x IgA
responses (r#20.58, p#0.015) (data not shown).
Discussion
Mucosal therapeutic vaccination has been poorly explored in
humans. Leroux-Roels et al. [30] recently described parenteral
prime and mucosal boosting with Env gp41 virosomes for
prophylactic use in healthy women based on promising data from
non-human primates [31]. In this study intranasal administration
of Vacc-4x with Endocine as a local adjuvant was well tolerated.
Without a booster phase, Vacc-4x-specific proliferative T cell
responses for both T cell subsets increased among the vaccinated
group from baseline to end of study as compared to the control
group that only received adjuvant.
Despite the limited number of patients receiving each dose,
dose-dependent differences in both cellular and humoral vaccine-
specific responses were observed. Vacc-4x CD8+T cell prolifera-
tive responses increased among low dose patients from baseline to
end of study and Vacc-4x DTH infiltrates were larger after
vaccination than among patients in the adjuvant group. Further-
more, the low dose induced better distal (rectal) Vacc-4x humoral
responses, although at lower levels than in nasal secretions. In
contrast, the high dose generated higher local (nasal) IgA and
serum IgG levels. These observations suggest that the mucosal
HIV antigen dose may be one factor directing the immune
response modality in chronically infected patients.
Inducing functional HIV-specific cellular immune responses at
mucosal sites might assist in controlling viral replication [32].
From a therapeutic HIV vaccine perspective, targeting chronic
HIV infection in the mucosa may be important [32]. The role of
mucosal antibodies is less clear. Mucosal HIV-specific IgA has
proven protective in individuals who have repeatedly been
exposed to HIV [33,34] but these responses are scarce in
chronically infected patients [35]. Since Vacc-4x reduces viral
load set points after treatment interruption [13], future vaccine
studies should provide an opportunity to study mucosal biopsies
and viral load measured by an ultra-sensitive HIV RNA assay.
In chronic infection, HIV-specific T cell responses are often
dysfunctional [23,36] and hampered by early clonal T cell loss
[37]. Therefore, many chronically infected patients have insuffi-
cient in vitro T cell responses to Gag. Results from our present
study also showed weak responses to the Vacc-4x Gag p24
consensus peptides. The T cell responses induced by intranasal
Figure 3. Vacc-4x proliferative T cell responses. A. Individual responses at baseline (week1) and end of study (week 8) for CD4+ (upper panels)
and CD8+ (lower panels) T cell subsets in the adjuvant (left) and the vaccinated (right) group. Doses are indicated as solid (low), dashed (median) or
dotted (high dose) lines, respectively. B. Responses in both T cell subsets at baseline (week 1) and end of study (week 8) in the adjuvant (Adj) and the
vaccinated group (Vacc), respectively. Changes within each group are indicated (Wilcoxon matched pairs test). C. Changes (D) in responses from
baseline to end of study in the four dose groups. Adj = adjuvant, LD = low, MD = median and HD = high dose. Data are given as medians,
interquartile and overall ranges. Significant differences between dose groups and the adjuvant group are indicated (Mann-Whitney U test).
doi:10.1371/journal.pone.0112556.g003
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administration of Vacc-4x were generally weaker than in former
trials, but patients in the former studies were given more
immunizations as well as boosters. Additional booster immuniza-
tions may have contributed to the durable T cell responses
observed [11,12]. Regardless, the relevance of vaccine-induced T
cell responses in vitro was supported by in vivo data that showed
larger Vacc-4x DTH infiltrates among the vaccinated as
compared to the adjuvant group. The Vacc-4x DTH skin test is
a reliable indicator of cellular immune responses in vivo [38].
T cell proliferation was the main in vitro outcome in accordance
with former Vacc-4x trials. Proliferation is fundamental for
effective immune responses and is a standard and robust method
for characterizing T cell functionality [39–42]. We have presented
proliferation as raw data that resulted in some cases of negative
proliferative responses, i.e. negative net responses were obtained
when adjusting for background proliferation in unstimulated
control cultures. There are several possible explanations for these
negative values. First, toxic byproducts from the peptide synthesis
process could be present, but this is unlikely because even positive
Figure 4. Relation between regulation and in vitro and in vivo T cell responses. A. Relation between Vacc-4x-induced regulation at baseline
and change (D) in Vacc-4x proliferative T cell responses from baseline to end of study in the CD4+T cell subset (vaccinated group). Spearman rank
correlation and p-value are indicated. B. Relation between Vacc-4x-induced regulation in the CD4+T cell subset and Vacc-4x DTH induration at week
8 (vaccinated group). Spearman rank correlation and p-value are indicated.
doi:10.1371/journal.pone.0112556.g004
Figure 5. Vacc-4x Ig antibody levels. Changes (D) from baseline to end of study in rectal IgA, nasal IgA and serum IgG antibody levels in the four
dose groups. Adj = adjuvant, LD = low, MD = median and HD = high dose. IgA antibody levels are adjusted to total IgA in rectal and nasal samples
(please note different scales). Data are given as medians, interquartile and overall ranges. Differences between dose groups and the adjuvant group
with p-values less than 0.10 are indicated (Mann-Whitney U test). Kruskal-Wallis ANOVA analysis for all four groups yielded p= 0.044 (rectal IgA),
p = 0.093 (nasal IgA) and p= 0.067 (serum IgG).
doi:10.1371/journal.pone.0112556.g005
Intranasal Therapeutic HIV Vaccine
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responses were obtained with the same peptide batches. Second,
assay variation around zero may occur among patients with low
vaccine-specific responses. However, negative responses were
repeatedly found in the same patients. Alternatively, Vacc-4x T
cell responses in some patients are strongly regulated by
mechanisms that reduce even the background proliferation in
Vacc-4x-stimulated cultures, resulting in negative net proliferation
relative to the corresponding unstimulated control culture. This is
in accordance with variable frequencies and suppressive functions
of specific regulatory T cells after therapeutic vaccination with
autologous dendritic cells loaded with HIV peptides [24]. Based
on recent observations [25,26], we therefore tested immune
regulation by blocking IL-10, an anti-inflammatory cytokine, and
TGF-b, a regulatory protein, in Vacc-4x-stimulated cell cultures.
This regulatory parameter has been associated with rapid disease
progression in untreated individuals [26] and might explain the
inconsistent effects observed following two Vacc-4x booster doses
in patients on ART [25]. In the present study we found that Vacc-
4x-induced regulation could explain most cases of negative
proliferation.
Vacc-4x regulation was predictive in other respects as well.
Vacc-4x DTH infiltrates were inversely correlated with concurrent
regulation after vaccination. Moreover, patients who showed the
greatest improvement in proliferative T cell responses had higher
levels of regulation at baseline. This may indicate that the balance
between Vacc-4x-induced T cell activation and regulation may be
altered by intranasal administration of Vacc-4x. Given that our
exploratory regulatory parameter is clinically relevant, patients
with vaccine-induced regulation at baseline might profit from
intranasal therapeutic vaccination. In contrast, we observed cases
of enhanced regulation after late boosters in intradermal
immunization [25]. Altogether, our observations indicate that it
might be advantageous to select candidates for therapeutic
vaccination trials based on both specific T cell responses and
regulation at screening. Furthermore, these parameters might be
valuable in monitoring vaccine responses and thereby individual-
ize therapeutic vaccination.
The choice of Vacc-4x doses given was based in part on
experience from previous Vacc-4x trials with intradermal injec-
tions even though the low dose in this study was only 1/5 of the
intradermal low dose [11]. The finding that low dose generated
the best proliferative T cell responses but no increase in local IgA
antibody levels may indicate that this dose induced a more Th1-
like response than the higher doses of Vacc-4x. The potential for
different antigen doses to direct immune responses in nasal
therapeutic vaccination remains to be determined.
In conclusion, we showed that intranasal administration of
Vacc-4x with Endocine as adjuvant was safe and induced dose-
dependent vaccine-specific T cell responses and both mucosal and
systemic humoral responses. The clinical significance of these
findings should be addressed in larger cohorts. The impact of
vaccine antigen doses and immune regulatory mechanisms
warrants further investigation.
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